Literature DB >> 22553629

Troglitazone induced apoptosis of human pterygium fibroblasts through a mitochondrial-dependent pathway.

Xiao-Xi Yang1, Jian Chen, Qing Zhou, Xian-Yin Guo, Pan Xiao, Jing Wu, Jin-Tang Xu.   

Abstract

AIM: To study the effect of troglitazone on primary culture human pterygium fibroblasts (HPF).
METHODS: Cell viability loss and apoptosis were quantified by cell counting kit-8, AnnexinV-FITC/PI double staining, caspases activity test and western blotting. Flow cytometry was used to detect mitochondrial membrane potential.
RESULTS: Peroxisome proliferator-activated receptor γ (PPAR-γ) was positively expressed in pterygium specimens (n=5). Troglitazone showed dose-dependent inhibition of cell survival, induced phospholipids redistribution, activated caspase-3, -9, and altered mitochondrial potential. Western blot assay demonstrated the increase of Bax/Bcl-2 protein ratio.
CONCLUSION: Troglitazone induced apoptosis of HPF through a mitochondrial-dependent pathway.

Entities:  

Keywords:  apoptosis; peroxisome proliferator-activated receptor γ; pterygium; troglitazone

Year:  2011        PMID: 22553629      PMCID: PMC3340713          DOI: 10.3980/j.issn.2222-3959.2011.02.06

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  11 in total

Review 1.  Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases.

Authors:  Nick Di Girolamo; Jeanie Chui; Minas T Coroneo; Denis Wakefield
Journal:  Prog Retin Eye Res       Date:  2004-03       Impact factor: 21.198

2.  Investigation of nitric oxide in pterygium.

Authors:  Gokhan Ozdemir; Fatma Inanc; Metin Kilinc
Journal:  Can J Ophthalmol       Date:  2005-12       Impact factor: 1.882

3.  UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling.

Authors:  Nick Di Girolamo; Denis Wakefield; Minas T Coroneo
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-06       Impact factor: 4.799

Review 4.  Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?

Authors:  D L Feinstein; A Spagnolo; C Akar; G Weinberg; P Murphy; V Gavrilyuk; C Dello Russo
Journal:  Biochem Pharmacol       Date:  2005-07-15       Impact factor: 5.858

5.  Fibroblasts isolated from human pterygia exhibit altered lipid metabolism characteristics.

Authors:  Enrico Peiretti; Sandra Dessì; Maria F Mulas; Claudia Abete; Maria S Galantuomo; Maurizio Fossarello
Journal:  Exp Eye Res       Date:  2006-05-11       Impact factor: 3.467

6.  Detection of point mutations at codon 12 of KI-ras in ophthalmic pterygia.

Authors:  E T Detorakis; A Zafiropoulos; D A Arvanitis; D A Spandidos
Journal:  Eye (Lond)       Date:  2005-02       Impact factor: 3.775

Review 7.  Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis.

Authors:  Costas Giaginis; Athina Giagini; Stamatios Theocharis
Journal:  Pharmacol Res       Date:  2009-02-14       Impact factor: 7.658

8.  Rosiglitazone and delayed onset of proliferative diabetic retinopathy.

Authors:  Lucy Q Shen; Angie Child; Griffin M Weber; Judah Folkman; Lloyd Paul Aiello
Journal:  Arch Ophthalmol       Date:  2008-06

9.  Effect of overexpression of PPARgamma on the healing process of corneal alkali burn in mice.

Authors:  Shizuya Saika; Osamu Yamanaka; Yuka Okada; Takeshi Miyamoto; Ai Kitano; Kathleen C Flanders; Yoshitaka Ohnishi; Yuji Nakajima; Winston W-Y Kao; Kazuo Ikeda
Journal:  Am J Physiol Cell Physiol       Date:  2007-07       Impact factor: 4.249

10.  PPARs in Eye Biology and Disease.

Authors:  Suofu Qin; Roy S Chuck
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

View more
  1 in total

Review 1.  Role of Peroxisome Proliferator-Activated Receptor γ in Ocular Diseases.

Authors:  Su Zhang; Hongwei Gu; Nan Hu
Journal:  J Ophthalmol       Date:  2015-06-04       Impact factor: 1.909

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.